Juan Manuel Sacnun

Mr. Juan Manuel Sacnun

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
RHRebecca Herzog
Rebecca Herzog
JSJuan Manuel Sacnun
Juan Manuel Sacnun
GGGuadalupe Tirma González-Mateo
Guadalupe Tirma González-Mateo
MBMaria Bartosova
Maria Bartosova
KBKatarzyna Bialas
Katarzyna Bialas
KKKlaus Kratochwill
Klaus Kratochwill
Lithium added to peritoneal dialysis fluid protects mesothelial cells and attenuates peritoneal fibrosis and angiogenesis by reducing αB-crystallin.

15 December 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
RHRebecca Herzog
Rebecca Herzog
MBMaria Bartosova
Maria Bartosova
STSilvia Tarantino
Silvia Tarantino
AWAnja Wagner
Anja Wagner
MUMarkus Unterwurzacher
Markus Unterwurzacher
KKKlaus Kratochwill
Klaus Kratochwill
Long-term clinical outcome of peritoneal dialysis (PD) depends on adequate removal of small solutes and water. The peritoneal endothelium represents the key barrier and peritoneal transport dysfunction is associated with vascular changes. Alanyl-glutamine (AlaGln) has been shown to counteract PD-induced deteriorations but the effect on vascular changes has not yet been elucidated. Using multiplexed proteomic and bioinformatic analyses we investigated the molecular mechanisms of vascular pathology in-vitro (primary human umbilical vein endothelial cells, HUVEC) and ex-vivo (arterioles of patients undergoing PD) following exposure to PD-fluid. An overlap of 1813 proteins (40%) of over 3100 proteins was identified in both sample types. PD-fluid treatment significantly altered 378 in endothelial cells and 192 in arterioles. The HUVEC proteome resembles the arteriolar proteome with expected sample specific differences of mainly immune system processes only present in arterioles and extracellular region proteins primarily found in HUVEC. AlaGln-addition to PD-fluid revealed 359 differentially abundant proteins and restored the molecular process landscape altered by PD fluid. This study provides evidence on validity and inherent limitations of studying endothelial pathomechanisms in-vitro compared to vascular ex-vivo findings. AlaGln could reduce PD-associated vasculopathy by reducing endothelial cellular damage, restoring perturbed abundances of pathologically important proteins and enriching protective processes.

10 January 2020 in The Plant Journal
Verified
Journal Article
Closed access
PDF file
JSJuan Manuel Sacnun
Juan Manuel Sacnun
RCRoberta Crespo
Roberta Crespo
JPJavier Palatnik
Javier Palatnik
RRRodolfo Rasia
Rodolfo Rasia
NGNahuel González‐Schain
Nahuel González‐Schain

Verified
Journal Article
Open access
PDF file
JSJuan Manuel Sacnun
Juan Manuel Sacnun
RHRobin Hoogenboom
Robin Hoogenboom
FEFabian Eibensteiner
Fabian Eibensteiner
ISIsabel J. Sobieszek
Isabel J. Sobieszek
MUMarkus Unterwurzacher
Markus Unterwurzacher
KKKlaus Kratochwill
Klaus Kratochwill
To replace kidney function, peritoneal dialysis (PD) utilizes hyperosmotic PD fluids with specific physico-chemical properties. Their composition induces progressive damage of the peritoneum, leading to vasculopathies, decline of membrane function, and PD technique failure. Clinically used PD fluids differ in their composition but still remain bioincompatible. We mapped the molecular pathomechanisms in human endothelial cells induced by the different characteristics of widely used PD fluids by proteomics. Of 7894 identified proteins, 3871 were regulated at least by 1 and 49 by all tested PD fluids. The latter subset was enriched for cell junction-associated proteins. The different PD fluids individually perturbed proteins commonly related to cell stress, survival, and immune function pathways. Modeling two major bioincompatibility factors of PD fluids, acidosis, and glucose degradation products (GDPs) revealed distinct effects on endothelial cell function and regulation of cellular stress responses. Proteins and pathways most strongly affected were members of the oxidative stress response. Addition of the antioxidant and cytoprotective additive, alanyl-glutamine (AlaGln), to PD fluids led to upregulation of thioredoxin reductase-1, an antioxidant protein, potentially explaining the cytoprotective effect of AlaGln. In conclusion, we mapped out the molecular response of endothelial cells to PD fluids, and provided new evidence for their specific pathomechanisms, crucial for improvement of PD therapies.

Verified
Journal Article
Open access
PDF file
MEMichail Evgeniou
Michail Evgeniou
JSJuan Manuel Sacnun
Juan Manuel Sacnun
KKKlaus Kratochwill
Klaus Kratochwill
PPPaul Perco
Paul Perco
Peritoneal dialysis (PD) is one therapeutic option for patients with end-stage kidney disease (ESKD). Molecular profiling of samples from PD patients using different Omics technologies has led to the discovery of dysregulated molecular processes due to PD treatment in recent years. In particular, a number of transcriptomics (TX) datasets are currently available in the public domain in the context of PD. We set out to perform a meta-analysis of TX datasets to identify dysregulated receptor-ligand interactions in the context of PD-associated complications. We consolidated transcriptomics profiles from twelve untargeted genome-wide gene expression studies focusing on human cell cultures or samples from human PD patients. Gene set enrichment analysis was used to identify enriched biological processes. Receptor-ligand interactions were identified using data from CellPhoneDB. We identified 2591 unique differentially expressed genes in the twelve PD studies. Key enriched biological processes included angiogenesis, cell adhesion, extracellular matrix organization, and inflammatory response. We identified 70 receptor-ligand interaction pairs, with both interaction partners being dysregulated on the transcriptional level in one of the investigated tissues in the context of PD. Novel receptor-ligand interactions without prior annotation in the context of PD included BMPR2-GDF6, FZD4-WNT7B, ACKR2-CCL2, or the binding of EPGN and EREG to the EGFR, as well as the binding of SEMA6D to the receptors KDR and TYROBP. In summary, we have consolidated human transcriptomics datasets from twelve studies in the context of PD and identified sets of novel receptor-ligand pairs being dysregulated in the context of PD that warrant investigation in future functional studies.

5 October 2022 in Cells
Verified
Journal Article
Open access
PDF file
IMIva Marinovic
Iva Marinovic
MBMaria Bartosova
Maria Bartosova
RHRebecca Herzog
Rebecca Herzog
JSJuan Manuel Sacnun
Juan Manuel Sacnun
CZConghui Zhang
Conghui Zhang
CSClaus Peter Schmitt
Claus Peter Schmitt
In vitro studies are essential in pre-clinical research. While choice of cell lines is often driven by handling and cost-effectiveness, in-depth knowledge on specific characteristics is scant. Mesothelial cells, which interact with endothelial cells, are widely used in research, including cancer and drug development, but have not been comprehensively profiled. We therefore performed RNA sequencing of polarized, primary peritoneal (HPMC) and immortalized pleural mesothelial cells (MeT-5A), and compared them to endothelial cells from umbilical vein (HUVEC) and cardiac capillaries (HCMEC). Seventy-seven per cent of 12,760 genes were shared between the 4 cell lines, 1003 were mesothelial and 969 were endothelial cell specific. The transcripts reflected major differences between HPMC and MeT-5A in DNA-related processes, extracellular matrix, migration, proliferation, adhesion, transport, growth factor- and immune response, and between HUVEC and HCMEC in DNA replication, extracellular matrix and adhesion organization. Highly variable shared genes were related to six clusters, cell tissue origin and immortalization, but also cell migration capacity, cell adhesion, regulation of angiogenesis and response to hypoxia. Distinct, cell type specific biological processes were further described by cellular component-, molecular function- and Reactome pathway analyses. We provide crucial information on specific features of the most frequently used mesothelial and endothelial cell lines, essential for appropriate use.